DDI Drug Name |
DDI Drug ID |
Severity |
Mechanism |
Comorbidity |
REF |
Cilostazol |
DMZMSCT
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Cilostazol. |
Arterial occlusive disease [BD40]
|
[4] |
Roflumilast |
DMPGHY8
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Roflumilast. |
Asthma [CA23]
|
[5] |
Pentosan polysulfate |
DM2HRKE
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Pentosan polysulfate. |
Chronic pain [MG30]
|
[6] |
Ketoprofen |
DMRKXPT
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ketoprofen. |
Chronic pain [MG30]
|
[4] |
Levomilnacipran |
DMV26S8
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Levomilnacipran. |
Chronic pain [MG30]
|
[7] |
Regorafenib |
DMHSY1I
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Regorafenib. |
Colorectal cancer [2B91]
|
[5] |
Ardeparin |
DMYRX8B
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ardeparin. |
Coronary thrombosis [BA43]
|
[4] |
Rivaroxaban |
DMQMBZ1
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Rivaroxaban. |
Deep vein thrombosis [BD71]
|
[4] |
Sertraline |
DM0FB1J
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Sertraline. |
Depression [6A70-6A7Z]
|
[7] |
Fluoxetine |
DM3PD2C
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Fluoxetine. |
Depression [6A70-6A7Z]
|
[7] |
Vilazodone |
DM4LECQ
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Vilazodone. |
Depression [6A70-6A7Z]
|
[7] |
Paroxetine |
DM5PVQE
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Paroxetine. |
Depression [6A70-6A7Z]
|
[7] |
Vortioxetine |
DM6F1PU
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Vortioxetine. |
Depression [6A70-6A7Z]
|
[7] |
Duloxetine |
DM9BI7M
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Duloxetine. |
Depression [6A70-6A7Z]
|
[7] |
Milnacipran |
DMBFE74
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Milnacipran. |
Depression [6A70-6A7Z]
|
[7] |
Escitalopram |
DMFK9HG
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Escitalopram. |
Depression [6A70-6A7Z]
|
[7] |
Desvenlafaxine |
DMHD4PE
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Desvenlafaxine. |
Depression [6A70-6A7Z]
|
[7] |
Clomipramine |
DMINRKW
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Clomipramine. |
Depression [6A70-6A7Z]
|
[7] |
Fluvoxamine |
DMQTJSX
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Fluvoxamine. |
Depression [6A70-6A7Z]
|
[7] |
Venlafaxine |
DMR6QH0
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Venlafaxine. |
Depression [6A70-6A7Z]
|
[7] |
Apigenin |
DMI3491
|
Minor |
Increased risk of bleeding by the combination of Tositumomab and Apigenin. |
Discovery agent [N.A.]
|
[8] |
Citalopram derivative 1 |
DMITX1G
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Citalopram derivative 1. |
Discovery agent [N.A.]
|
[7] |
Fenfluramine |
DM0762O
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Fenfluramine. |
Epilepsy/seizure [8A61-8A6Z]
|
[7] |
Suprofen |
DMKXJZ7
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Suprofen. |
Eye anterior segment structural developmental anomaly [LA11]
|
[9] |
Mefenamic acid |
DMK7HFI
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Mefenamic acid. |
Female pelvic pain [GA34]
|
[4] |
Tazemetostat |
DMWP1BH
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Tazemetostat. |
Follicular lymphoma [2A80]
|
[4] |
Avapritinib |
DMK2GZX
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Avapritinib. |
Gastrointestinal stromal tumour [2B5B]
|
[5] |
Tipranavir |
DM8HJX6
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Tipranavir. |
Human immunodeficiency virus disease [1C60-1C62]
|
[10] |
Teriflunomide |
DMQ2FKJ
|
Major |
Additive immunosuppressive effects by the combination of Tositumomab and Teriflunomide. |
Hyper-lipoproteinaemia [5C80]
|
[11] |
Dipyridamole |
DMXY30O
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Dipyridamole. |
Hypertension [BA00-BA04]
|
[4] |
Meclofenamic acid |
DM05FXR
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Meclofenamic acid. |
Inflammatory spondyloarthritis [FA92]
|
[4] |
Ticlopidine |
DMO946V
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ticlopidine. |
Ischaemic/haemorrhagic stroke [8B20]
|
[4] |
Denosumab |
DMNI0KO
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Denosumab. |
Low bone mass disorder [FB83]
|
[12] |
Cladribine |
DM3JDRP
|
Major |
Additive immunosuppressive effects by the combination of Tositumomab and Cladribine. |
Mature B-cell leukaemia [2A82]
|
[5] |
Alemtuzumab |
DMZL3IV
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Alemtuzumab. |
Mature B-cell leukaemia [2A82]
|
[13] |
Acalabrutinib |
DM7GCVW
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Acalabrutinib. |
Mature B-cell lymphoma [2A85]
|
[14] |
Ibrutinib |
DMHZCPO
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ibrutinib. |
Mature B-cell lymphoma [2A85]
|
[15] |
Ponatinib |
DMYGJQO
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ponatinib. |
Mature B-cell lymphoma [2A85]
|
[16] |
Arry-162 |
DM1P6FR
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Arry-162. |
Melanoma [2C30]
|
[4] |
LGX818 |
DMNQXV8
|
Major |
Increased risk of bleeding by the combination of Tositumomab and LGX818. |
Melanoma [2C30]
|
[4] |
Tecfidera |
DM2OVDT
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Tecfidera. |
Multiple sclerosis [8A40]
|
[17] |
Siponimod |
DM2R86O
|
Major |
Additive immunosuppressive effects by the combination of Tositumomab and Siponimod. |
Multiple sclerosis [8A40]
|
[18] |
Fingolimod |
DM5JVAN
|
Major |
Additive immunosuppressive effects by the combination of Tositumomab and Fingolimod. |
Multiple sclerosis [8A40]
|
[19] |
Ocrelizumab |
DMEZ2KH
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Ocrelizumab. |
Multiple sclerosis [8A40]
|
[20] |
Ozanimod |
DMT6AM2
|
Major |
Additive immunosuppressive effects by the combination of Tositumomab and Ozanimod. |
Multiple sclerosis [8A40]
|
[5] |
Fedratinib |
DM4ZBK6
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Fedratinib. |
Myeloproliferative neoplasm [2A20]
|
[4] |
Ruxolitinib |
DM7Q98D
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ruxolitinib. |
Myeloproliferative neoplasm [2A20]
|
[4] |
Dasatinib |
DMJV2EK
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Dasatinib. |
Myeloproliferative neoplasm [2A20]
|
[4] |
Omacetaxine mepesuccinate |
DMPU2WX
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Omacetaxine mepesuccinate. |
Myeloproliferative neoplasm [2A20]
|
[6] |
Prasugrel |
DM7MT6E
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Prasugrel. |
Myocardial infarction [BA41-BA43]
|
[4] |
Vorapaxar |
DMA16BR
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Vorapaxar. |
Myocardial infarction [BA41-BA43]
|
[4] |
Tirofiban |
DMQG17S
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Tirofiban. |
Myocardial infarction [BA41-BA43]
|
[4] |
Sibutramine |
DMFJTDI
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Sibutramine. |
Obesity [5B80-5B81]
|
[21] |
Diclofenac |
DMPIHLS
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Diclofenac. |
Osteoarthritis [FA00-FA05]
|
[4] |
Nepafenac |
DMYK490
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Nepafenac. |
Osteoarthritis [FA00-FA05]
|
[9] |
Naproxen |
DMZ5RGV
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Naproxen. |
Osteoarthritis [FA00-FA05]
|
[4] |
Aspirin |
DM672AH
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Aspirin. |
Pain [MG30-MG3Z]
|
[4] |
Etodolac |
DM6WJO9
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Etodolac. |
Pain [MG30-MG3Z]
|
[4] |
Diflunisal |
DM7EN8I
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Diflunisal. |
Pain [MG30-MG3Z]
|
[4] |
Ibuprofen |
DM8VCBE
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ibuprofen. |
Pain [MG30-MG3Z]
|
[4] |
Nabumetone |
DMAT2XH
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Nabumetone. |
Pain [MG30-MG3Z]
|
[4] |
Piroxicam |
DMTK234
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Piroxicam. |
Pain [MG30-MG3Z]
|
[4] |
Ketorolac |
DMI4EL5
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Ketorolac. |
Postoperative inflammation [1A00-CA43]
|
[4] |
Bromfenac |
DMKB79O
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Bromfenac. |
Postoperative inflammation [1A00-CA43]
|
[9] |
Treprostinil |
DMTIQF3
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Treprostinil. |
Pulmonary hypertension [BB01]
|
[4] |
Epoprostenol |
DMUTYR2
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Epoprostenol. |
Pulmonary hypertension [BB01]
|
[4] |
Iloprost |
DMVPZBE
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Iloprost. |
Pulmonary hypertension [BB01]
|
[4] |
Meloxicam |
DM2AR7L
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Meloxicam. |
Rheumatoid arthritis [FA20]
|
[4] |
Sulindac |
DM2QHZU
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Sulindac. |
Rheumatoid arthritis [FA20]
|
[4] |
Canakinumab |
DM8HLO5
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Canakinumab. |
Rheumatoid arthritis [FA20]
|
[22] |
Oxaprozin |
DM9UB0P
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Oxaprozin. |
Rheumatoid arthritis [FA20]
|
[4] |
Rilonacept |
DMGLUQS
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Rilonacept. |
Rheumatoid arthritis [FA20]
|
[22] |
Flurbiprofen |
DMGN4BY
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Flurbiprofen. |
Rheumatoid arthritis [FA20]
|
[4] |
Golimumab |
DMHZV7X
|
Major |
Additive immunosuppressive effects by the combination of Tositumomab and Golimumab. |
Rheumatoid arthritis [FA20]
|
[23] |
Fenoprofen |
DML5VQ0
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Fenoprofen. |
Rheumatoid arthritis [FA20]
|
[4] |
Leflunomide |
DMR8ONJ
|
Major |
Additive immunosuppressive effects by the combination of Tositumomab and Leflunomide. |
Rheumatoid arthritis [FA20]
|
[11] |
Indomethacin |
DMSC4A7
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Indomethacin. |
Rheumatoid arthritis [FA20]
|
[4] |
Tolmetin |
DMWUIJE
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Tolmetin. |
Rheumatoid arthritis [FA20]
|
[4] |
Anthrax vaccine |
DM9GSWY
|
Moderate |
Antagonize the effect of Tositumomab when combined with Anthrax vaccine. |
Sepsis [1G40-1G41]
|
[24] |
Warfarin |
DMJYCVW
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Warfarin. |
Supraventricular tachyarrhythmia [BC81]
|
[4] |
Caplacizumab |
DMPUKA7
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Caplacizumab. |
Thrombocytopenia [3B64]
|
[4] |
Anagrelide |
DMSQ8MD
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Anagrelide. |
Thrombocytosis [3B63]
|
[4] |
Apixaban |
DM89JLN
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Apixaban. |
Thrombosis [DB61-GB90]
|
[4] |
Cangrelor |
DM8JRH0
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Cangrelor. |
Thrombosis [DB61-GB90]
|
[4] |
Brilinta |
DMBR01X
|
Moderate |
Increased risk of bleeding by the combination of Tositumomab and Brilinta. |
Thrombosis [DB61-GB90]
|
[5] |
Argatroban |
DMFI46A
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Argatroban. |
Thrombosis [DB61-GB90]
|
[4] |
Clopidogrel |
DMOL54H
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Clopidogrel. |
Thrombosis [DB61-GB90]
|
[4] |
Cabozantinib |
DMIYDT4
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Cabozantinib. |
Thyroid cancer [2D10]
|
[25] |
Azathioprine |
DMMZSXQ
|
Moderate |
Additive immunosuppressive effects by the combination of Tositumomab and Azathioprine. |
Transplant rejection [NE84]
|
[18] |
Betrixaban |
DM2C4RF
|
Major |
Increased risk of bleeding by the combination of Tositumomab and Betrixaban. |
Venous thromboembolism [BD72]
|
[4] |
Ganciclovir |
DM1MBYQ
|
Moderate |
Additive myelosuppressive effects by the combination of Tositumomab and Ganciclovir. |
Virus infection [1A24-1D9Z]
|
[18] |
Valganciclovir |
DMS2IUH
|
Moderate |
Additive myelosuppressive effects by the combination of Tositumomab and Valganciclovir. |
Virus infection [1A24-1D9Z]
|
[18] |
----------- |
|
|
|
|
|